Pherecydes Pharma

Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

Pherecydes Pharma headquartered in Europe, operates in the Biotechnology, Health Care, Medical Device sector. The company focuses on Biotechnology and has secured $1.2B in funding across 60 round(s). With a team of 11-50 employees, Pherecydes Pharma is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Pherecydes Pharma, raised $2.4M. Discover more about their projects, partnerships, and impact on our platform.